DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics segments. Founded in 2000 and headquartered in Saluggia, Italy, the... DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics segments. Founded in 2000 and headquartered in Saluggia, Italy, the company develops and markets in vitro diagnostics reagent kits for detecting antibodies and antigens, serving healthcare, life sciences, and academic research sectors. With approximately 3,271 employees and 2024 revenue of $1,282.9 million, DiaSorin operates across North America, Europe, and key geographies like Italy. A pivotal milestone was the 2021 acquisition of Luminex Corp., enhancing its portfolio with advanced molecular diagnostic technologies such as the ARIES and VERIGENE Systems, xMAP Technology, and companion diagnostics kits for cystic fibrosis and infectious diseases detection. DiaSorin also engages in the Licensed Technology sector, providing instruments like LIAISON systems for hepatitis delta testing and bloodstream infection diagnostics, empowering precise clinical responses worldwide. Over 50 years of expertise underpin its role in advancing diagnostic solutions for doctors, patients, and research institutions.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for DiaSorin

We have not yet reviewed DiaSorin's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review DiaSorin's data?

Start your 30-day free trial to request a data review for DiaSorin.

Start Free Trial

Legal Center Contact Us